The EdU incorporation assay confirmed that the inhibition of NAT10 using remodelin decreased the proliferation of all four HCC cell lines when treated with doxorubicin (Figures 1(e)–1(h) and Table 1). This evidence concerns the gene NAT10 and hepatocellular carcinoma.